Chiome Bioscience (TSE:4583) Retained Earnings: 円-2,003.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
42 GF Score
Price 円70.00
GF Value 円105.67
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Retained Earnings?

Chiome Bioscience TSE:4583 42 Retained Earnings is 円-2,003.6 Mil as of Dec. 2025. GuruFocus rates TSE:4583 with a GF Score™ of 42/100 and a GF Value™ of 円105.67 (Possible Value Trap). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Chiome Bioscience's retained earnings for the quarter that ended in Dec. 2025 was 円-2,003.6 Mil.

Chiome Bioscience's quarterly retained earnings declined from Jun. 2025 (円-1,561.1 Mil) to Sep. 2025 (円-1,821.0 Mil) and declined from Sep. 2025 (円-1,821.0 Mil) to Dec. 2025 (円-2,003.6 Mil).

Chiome Bioscience's annual retained earnings increased from Dec. 2023 (円-5,236.4 Mil) to Dec. 2024 (円-1,020.8 Mil) but then declined from Dec. 2024 (円-1,020.8 Mil) to Dec. 2025 (円-2,003.6 Mil).


Chiome Bioscience  (TSE:4583) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Chiome Bioscience Retained Earnings Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Retained Earnings Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,773.69 -4,016.33 -5,236.35 -1,020.78 -2,003.56

Chiome Bioscience Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,286.84 -1,561.07 -1,821.03 -2,003.56 -2,236.71
TSE:4583
42GF Score
Chiome Bioscience Inc TSE:4583
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of 円-2,003.6 Mil mean?
Chiome Bioscience (TSE:4583) has a Retained Earnings of 円-2,003.6 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's Retained Earnings too high?
Chiome Bioscience's current Retained Earnings is 円-2,003.6 Mil. Overall, Chiome Bioscience has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Retained Earnings compare to VRTX and REGN?
Chiome Bioscience's Retained Earnings of 円-2,003.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Retained Earnings is 円-2,003.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円105.67, compared to a current price of 円70.00 — trading 33.8% below its estimated fair value. The current Retained Earnings is 円-2,003.6 Mil. Chiome Bioscience's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Retained Earnings is 円-2,003.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円70.00 is trading 33.8% below its estimated GF Value™ of 円105.67. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • Retained Earnings: 円-2,003.6 Mil
  • GF Value™: 円105.67 vs. price of 円70.00 (33.8% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
42GF Score

Get the complete analysis for TSE:4583

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円70.00
Price
円105.67
GF Value